Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics

Biomedicine and Pharmacotherapy

Volumn 52, Issue 9, 1998, Pages 391-396

  Mathe G ^a   Triana, K ^a   Pontiggia, P ^a   Blanquet, D ^a   Hallard, M ^a   Morette, C ^a  

^a Hopital Suisse de Paris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; CD28 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; DIDANOSINE; ELLIPTICINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; SUPPRESSOR CELL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0032311179     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(99)80007-9     Document Type: Article

References (34)

1. 1 Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III-lymphadenopathy virus- associated virus (HTLV-III/LAV) by 2′-3′-dideoxynucleosides. Proc Nat Acad Sc 1986 ; 83 : 1911
2. 2 Fish MA, Richmann DD, Grieco MH. The efficacity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double blind placebo controlled trial. N Engl J Med 1987 ; 317 : 185
3. 3 Mathé G, Blaszek I, Florentin I et al. Correlation between oncostatic, differentiating, immunologic and virostatic agents actions. In: H Tapiero, J Robert, TL Lampidis, eds. Anticancer Drugs. Paris: INSERM/John Libbey; 1989. p 167-77
4. 4 Mathé G, Amiel JL. Reduction de la concentration plasmatique du virus leucémigène de Charlotte Friend par immunothérapie adoptive (greffe de moelle osseuse allogénique). C R Acad Sc 1964 ; 259 : 4403
5. 5 Mathé G, Amiel JL, Friend AC. Essai de traitement de la leucémie de Charlotte Friend par la greffe de cellules hematopoietiques de donneurs isogéniques vaccinés contre le virus. Bull Cancer 1962 ; 49 : 416
6. 6 Clarysse A, Kenis Y, Mathé G. Cancer Chemotherapy. Springer: New-York; 1976
7. 7 Peter V, Hartwell JL, Dalton AJ et al. First screening in tumor bearing mice: segregation of active from inactive compounds. In: Proceedings of Scientific Sessions of Am Assc Cancer Res Inc 37th Annual Meeting, March 11-12; 1946: p 490
8. 8 Le Men J, Hayat M, Mathé G et al. Methoxy-9-ellipticine lactate I. Experimental study (oncostatic and immunosuppressive actions; preclinical pharmacology). Rev Europ Et Clin Biol 1970 ; 15 : 534
9. 9 Hayat M, Mathé G, Potier P et al. Experimental screening of 3 forms and 19 derivatives or analogs of ellipticine; oncostatic effect on L 1210 leukaemia and immunosuppressive effect of 4 of them. Biomed Pharmacother 1974 ; 21 : 101
10. 10 Mathé G, Hayat M, De Vassal F et al. Methoxy-9-ellipticine lactose III. Clinical screening and action in myeloblastic leukemia. Europ J Clin Biol Res 1970 ; 15 : 541
11. 11 Paoletti C, Auclair C, Lesca P et al. Ellipticine, 9 hydroxy-ellipticine and 9-hydroxyellipticinium: some biomedical properties of possible pharmacologic significance. Cancer Treatment Rep 1981 ; 65 suppl 3 : 107
12. 12 Kreuzer KN. DNA topoisomerases as potential targets of anti-viral action. Pharmacol Therap 1989 ; 43 : 377
13. 13 Fosse P, René B, Le Bret M. Sequence requirements for mammal an topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acid Res 1991 ; 19 :2861
14. 14 Mathé G, Huppert J, Chenu E, Bourut C. Amino-acridines action on Friend's retrovirus in relation to their molecular ionisation. Biomed Pharmacother 1989 ; 43 : 235
15. 15 Davies RH, Williams H, Smith HJ. Intermolecular forces and stereospecificity in drug action. In: Introduction to the Principles of Drug Design. London: Wright; 1988
16. 16 Adriapharm. Pharmacopée Française. Xème éd. Paris: Maisonneuve; 1995
17. 17 Boyd ML. Treatment of early acute anterior uretristis with acriflavine. Urol Cutan Rev 1930 ; 34 : 303
18. 18 Assinder E. Acridine as a urinary antiseptic. Lancet 1936 : 304
19. 19 Mathé G, Triana K. Antiviral phase I-II trial of acriflavine in HIV1 infected patients. In: Sixth Intern Conf on AIDS 20-24 June, San Francisco; 1990
20. 20 Mathé G, Pontiggia P. A screening model of anti-HIV non AZT cross resistances virostatics. Biomed Pharmacother 1993 ; 47 : 461
21. 21 Merigan TC, Shovron G, Bozetts SA et al. Circulating p 24 antigen levels and responses to dideoxycytidine (ddC) in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989 ; 110 : 189
22. 22 Lambert JS, Seidlin M, Reichman RC et al. 2′-3′ Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS related complex. N Engl J Med 1990 ; 322 : 1333
23. 23 Saag MS. Nucleoside analogues: Adverse effects. Hosp Pract 1992 ; 27 : 26
24. 24 Richman DD. Viral resistance to anti-retroviral therapy. In: S Broder, TC Merigan, D Bolognesi, eds. Textbook of AIDS Medicine. Baltimore: Williams and Wilkins; 1994
25. 25 Mathé G, Chenu E, Bourut C. Virostatic in vivo effect of elliptinium on Friend's retrovirus (a model of HIV infection). Biomed Pharmacother 1990 ; 44 : 1
26. 26 Mathé G, Chenu E, Bourut C. The in vivo effect of ellipticine analogues on the blood concentration of Friend's virus: a murine model for studying anti-HIV drugs. Biomed Pharmacother 1993 ; 47 : 457
27. 27 Mathé G, Pontiggia P, Orbach-Arbouys S et al. AIDS therapy with two, three or four agent combinations applied in short sequences differing from each other by drug rotation. I first of two parts: a phase I trial equivalent concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue. Biomed Pharmacother 1996 ; 50 : 200
28. 28 Mathé G. Preliminary results of an experimental and clinical phase I-II trial in AIDS. In: Overview and Status of HIV: Conference on the Disease, Prevention and/or Control. Pavia; 1995. p 15
29. 1-AIDS complex. Biomed Pharmacother 1996 ; 50 : 510-11
30. 30 Larder BA, Kemp SA, Harrigan PRI. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995 ; 269 : 696-9
31. 31 Pavia AT, Gather J, BMS-019 Stdy Group Investigators et al. Clinical efficacy of stavudine (d4T Zerit) compared to zidovudine (ZDV, Retrovir) in ZVD-pretreated HIV positive patients. In: Proceedings of 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 1995. p 235
32. 32 Kitchen VS, Skinner C, Arigoshi K et al. Safety and activity of saquinavir in HIV infection. Lancet 1995 ; 345 : 952-5
33. 33 Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV1 protease. European Australian Collaborative Ritonavir Group. N Engl J Med 1995 ; 333 : 1528-33
34. 34 Vacca JP, Dorsey BD, Schleif WA et al. L-735, 524: an orally biovalable human imuunodeficiency virus type I protease inhibitor. Proc Natl Acad Sci USA 1994 ; 91 : 4096-100